Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

BACKGROUND: The antiviral drug molnupiravir was licensed for treating at-risk patients with COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety and virological efficacy of molnupiravir in vaccinated and unvaccinated individuals with COVID-19. METHODS: This randomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Khoo, Saye H, FitzGerald, Richard, Saunders, Geoffrey, Middleton, Calley, Ahmad, Shazaad, Edwards, Christopher J, Hadjiyiannakis, Dennis, Walker, Lauren, Lyon, Rebecca, Shaw, Victoria, Mozgunov, Pavel, Periselneris, Jimstan, Woods, Christie, Bullock, Katie, Hale, Colin, Reynolds, Helen, Downs, Nichola, Ewings, Sean, Buadi, Amanda, Cameron, David, Edwards, Thomas, Knox, Emma, Donovan-Banfield, I'ah, Greenhalf, William, Chiong, Justin, Lavelle-Langham, Lara, Jacobs, Michael, Northey, Josh, Painter, Wendy, Holman, Wayne, Lalloo, David G, Tetlow, Michelle, Hiscox, Julian A, Jaki, Thomas, Fletcher, Thomas, Griffiths, Gareth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662684/
https://www.ncbi.nlm.nih.gov/pubmed/36272432
http://dx.doi.org/10.1016/S1473-3099(22)00644-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662684/
https://www.ncbi.nlm.nih.gov/pubmed/36272432
http://dx.doi.org/10.1016/S1473-3099(22)00644-2

Ejemplares similares